The mechanism appears to be GLP-1 receptor activation in the brain's reward pathways, which attenuates dopamine release in the nucleus accumbens and reduces the reward signal from alcohol
On the other hand, administration of tirzepatide at a dose of 70 nmol/kg/day, resulted in a significant weight loss associated with shorter femur compared to saline-treated diabetic mice, but no evident alterations of bone microarchitecture or strength [69]
This effect is dose-dependent, with appetite suppression often increasing during dose titration (usually starting at 0.25mg weekly, then increasing to 0.5mg or 1mg)
Step-up dosages: Participants then increased their dose strength every 4 weeks, first to 4 mg, then 6 mg, then 9 mg, then 12 mg, depending on their assigned maintenance dose
Macroalbuminuria occurred less (2.2%) in exenatide group compared to placebo group (2.5%) [HR 0.87 (95% CI: 0.701.07)]